Oral Cancer Detection Increased with Saliva Test
|
By LabMedica International staff writers Posted on 10 May 2012 |
A simple saliva test has been created which could identify the presence of biomarkers that are associated with oral cancer.
The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.
A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.
Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."
Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.
Related Links:
Michigan State University
University of California
Delta Dental
The easy, cost-effective saliva test to detect oral cancer would be a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.
A surgical team at Michigan State University (East Lansing, MI, USA) is teaming up with a local area dental benefits firm for a clinical trial of the saliva test that will aid physicians and dentists to know which patients need treatment and which ones could avoid needless and invasive biopsies. The scientists will be looking for certain biomarkers previously identified by researchers at the University of California (UCLA; Los Angeles, CA, USA). The biomarkers have been shown in studies to confirm the presence of oral cancer.
Barry Lloyd Wenig, MD, MPH, PhD, a professor of otolaryngology and lead investigator said, "Most white lesions are benign, so a majority of people who develop them are getting biopsies that are not needed. Conversely, a simple test would allow us to identify those patients with malignant lesions and get them into treatment quicker. These tests are as noninvasive as it gets; patients simply need to spit into a cup. The ease of the test will greatly expand our ability to effectively screen for the cancerous lesions. Right now, there are no early screenings available for most head and neck cancers."
Prof. Wenig is teaming up with Delta Dental (Okemos, MI, USA) which works with scientists from leading universities to monitor advances in science. Their chief science officer, Jed J. Jacobson, DDS, MPH, said, "The results of this trial could be life changing for many people. It is a tremendous opportunity for the dental community to participate in what could be a groundbreaking project.” Oral cancer has a poor survival rate linked to late detection; only 60% of patients live beyond five years after diagnosis. The survival rate is less than 38% among black males.
Related Links:
Michigan State University
University of California
Delta Dental
Latest Pathology News
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more
Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease
Liver disease can progress silently until treatment options become more limited. Routine blood panels measure markers such as cholesterol, bilirubin, and triglycerides but typically do not include bile... Read more
Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease
Chronic kidney disease (CKD) is a major cause of mortality worldwide and often progresses silently until advanced stages. Despite the availability of simple urine and blood tests, many cases remain undetected,... Read more
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more





.jpg)

